{"id":"ergocalciferol","rwe":[{"pmid":"41777703","year":"2026","title":"Vitamin D deficiency and disease conditions relevant to: Orthopaedic translation.","finding":"","journal":"Journal of orthopaedic translation","studyType":"Clinical Study"},{"pmid":"41219601","year":"2026","title":"Vitamin D and Fracture Healing.","finding":"","journal":"Advances in experimental medicine and biology","studyType":"Clinical Study"},{"pmid":"41219598","year":"2026","title":"Vitamin D and Brain Health.","finding":"","journal":"Advances in experimental medicine and biology","studyType":"Clinical Study"},{"pmid":"41163646","year":"2025","title":"A 3-Year-Old Child With Incidental High-Dose Vitamin D Intoxication: A Case Report and Literature Review.","finding":"","journal":"Case reports in endocrinology","studyType":"Clinical Study"},{"pmid":"41154052","year":"2025","title":"Himalayan Mushrooms as a Natural Source of Ergosterol and Vitamin D(2): A Review of Nutraceutical and Functional Food Perspectives.","finding":"","journal":"Foods (Basel, Switzerland)","studyType":"Clinical Study"}],"_fda":{"id":"0d230fd8-2ea7-4dd6-a506-5f7804e539fc","set_id":"0d230fd8-2ea7-4dd6-a506-5f7804e539fc","openfda":{"nui":["M0007651","N0000175909"],"unii":["VS041H42XC"],"route":["ORAL"],"rxcui":["1367410"],"spl_id":["0d230fd8-2ea7-4dd6-a506-5f7804e539fc"],"brand_name":["Ergocalciferol"],"spl_set_id":["0d230fd8-2ea7-4dd6-a506-5f7804e539fc"],"package_ndc":["71335-2246-1","71335-2246-2","71335-2246-3"],"product_ndc":["71335-2246"],"generic_name":["ERGOCALCIFEROL"],"product_type":["HUMAN PRESCRIPTION DRUG"],"pharm_class_cs":["Ergocalciferols [CS]"],"substance_name":["ERGOCALCIFEROL"],"pharm_class_epc":["Provitamin D2 Compound [EPC]"],"manufacturer_name":["Bryant Ranch Prepack"],"application_number":["ANDA080704"],"original_packager_product_ndc":["69452-151"]},"version":"102","warnings":["WARNINGS Hypersensitivity to vitamin D may be one etiologic factor in infants with idiopathic hypercalcemia. In these cases vitamin D must be strictly restricted. Keep out of the reach of children."],"pregnancy":["Pregnancy Category C Animal reproduction studies have shown fetal abnormalities in several species associated with hypervitaminosis D. These are similar to the supravalvular aortic stenosis syndrome described in infants by Black in England (1963). This syndrome was characterized by supravalvular aortic stenosis, elfin facies, and mental retardation. For the protection of the fetus, therefore, the use of vitamin D in excess of the recommended dietary allowance during normal pregnancy should be avoided unless, in the judgment of the physician, potential benefits in a specific, unique case outweigh the significant hazards involved. The safety in excess of 400 USP units of vitamin D daily during pregnancy has not been established."],"overdosage":["OVERDOSAGE The effects of administered vitamin D can persist for two or more months after cessation of treatment. Hypervitaminosis D is characterized by: Hypercalcemia with anorexia, nausea, weakness, weight loss, vague aches and stiffness, constipation, mental retardation, anemia, and mild acidosis. Impairment of renal function with polyuria, nocturia, polydipsia, hypercalciuria, reversible azotemia, hypertension, nephrocalcinosis, generalized vascular calcification, or irreversible renal insufficiency which may result in death. Widespread calcification of the soft tissues, including the heart, blood vessels, renal tubules, and lungs. Bone demineralization (osteoporosis) in adults occurs concomitantly. Decline in the average rate of linear growth and increased mineralization of bones in infants and children (dwarfism). The treatment of hypervitaminosis D with hypercalcemia consists in immediate withdrawal of the vitamin, a low calcium diet, generous intake of fluids, along with symptomatic and supportive treatment. Hypercalcemic crisis with dehydration, stupor, coma, and azotemia requires more vigorous treatment. The first step should be hydration of the patient. Intravenous saline may quickly and significantly increase urinary calcium excretion. A loop diuretic (furosemide or ethacrynic acid) may be given with the saline infusion to further increase renal calcium excretion. Other reported therapeutic measures include dialysis or the administration of citrates, sulfates, phosphates, corticosteroids, EDTA (ethylenediaminetetraacetic acid), and mithramycin via appropriate regimens. With appropriate therapy, recovery is the usual outcome when no permanent damage has occurred. Deaths via renal or cardiovascular failure have been reported. The LD 50 in animals is unknown. The toxic oral dose of ergocalciferol in the dog is 4 mg/kg."],"description":["DESCRIPTION ERGOCALCIFEROL CAPSULES, USP, is a synthetic calcium regulator for oral administration. Ergocalciferol is a white, colorless crystal, insoluble in water, soluble in organic solvents, and slightly soluble in vegetable oils. It is affected by air and by light. Ergosterol or provitamin D 2 is found in plants and yeast and has no antirachitic activity. There are more than 10 substances belonging to a group of steroid compounds, classified as having vitamin D or antirachitic activity. One USP Unit of vitamin D 2 is equivalent to one International Unit (IU), and 1 mcg of vitamin D 2 is equal to 40 IU. Each softgel, for oral administration, contains Ergocalciferol, USP 1,250 mcg (equivalent to 50,000 USP units of Vitamin D), in an edible vegetable oil. Ergocalciferol, also called vitamin D 2 , is 9,10-secoergosta-5,7,10(19),22-tetraen-3-ol,(3 β ,5 Z ,7 E ,22 E )-; (C 28 H 44 O) with a molecular weight of 396.65, and has the following structural formula: Inactive Ingredients : Refined soybean oil, gelatin, glycerin, purified water, D&C Yellow #10, and FD&C Blue #1."],"precautions":["PRECAUTIONS General Vitamin D administration from fortified foods, dietary supplements, self-administered and prescription drug sources should be evaluated. Therapeutic dosage should be readjusted as soon as there is clinical improvement. Dosage levels must be individualized and great care exercised to prevent serious toxic effects. IN VITAMIN D RESISTANT RICKETS THE RANGE BETWEEN THERAPEUTIC AND TOXIC DOSES IS NARROW. When high therapeutic doses are used progress should be followed with frequent blood calcium determinations. In the treatment of hypoparathyroidism, intravenous calcium, parathyroid hormone, and/or dihydrotachysterol may be required. Maintenance of a normal serum phosphorous level by dietary phosphate restriction and/or administration of aluminum gels as intestinal phosphate binders in those patients with hyperphosphatemia as frequently seen in renal osteodystrophy is essential to prevent metastatis calcification. Adequate dietary calcium is necessary for clinical response to vitamin D therapy. Protect from light. Drug Interactions Mineral oil interferes with the absorption of fat-soluble vitamins, including vitamin D preparations. Administration of thiazide diuretics to hypoparathyroid patients who are concurrently being treated with ergocalciferol may cause hypercalcemia. Carcinogenesis, Mutagenesis, Impairment of Fertility No long-term animal studies have been performed to evaluate the drug's potential in these areas. Pregnancy Category C Animal reproduction studies have shown fetal abnormalities in several species associated with hypervitaminosis D. These are similar to the supravalvular aortic stenosis syndrome described in infants by Black in England (1963). This syndrome was characterized by supravalvular aortic stenosis, elfin facies, and mental retardation. For the protection of the fetus, therefore, the use of vitamin D in excess of the recommended dietary allowance during normal pregnancy should be avoided unless, in the judgment of the physician, potential benefits in a specific, unique case outweigh the significant hazards involved. The safety in excess of 400 USP units of vitamin D daily during pregnancy has not been established. Nursing Mothers Caution should be exercised when ergocalciferol is administered to a nursing woman. In a mother given large doses of vitamin D, 25-hydroxycholecalciferol appeared in the milk and caused hypercalcemia in her child. Monitoring of the infant's serum calcium concentration is required in that case (Goldberg, 1972). Pediatric Use Pediatric doses must be individualized (see DOSAGE AND ADMINISTRATION ). Geriatric Use Clinical studies of Ergocalciferol capsules, USP did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients. A few published reports have suggested that the absorption of orally administered vitamin D may be attenuated in elderly compared to younger individuals. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy."],"how_supplied":["HOW SUPPLIED Each green, oval softgel is imprinted with PA140 and contains 1,250 mcg (50,000 USP units vitamin D) of ergocalciferol, USP, and is available in NDC 71335-2246-1: 4 Capsules in a BOTTLE NDC 71335-2246-2: 12 Capsules in a BOTTLE NDC 71335-2246-3: 8 Capsules in a BOTTLE Store at 25° C (77° F); excursions permitted to 15° to 30° C (59° to 86° F) [See USP Controlled Room Temperature]. Protect from light and moisture. Dispense in a tight, light-resistant container as defined in the USP. Repackaged/Relabeled by: Bryant Ranch Prepack, Inc. Burbank, CA 91504"],"geriatric_use":["Geriatric Use Clinical studies of Ergocalciferol capsules, USP did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients. A few published reports have suggested that the absorption of orally administered vitamin D may be attenuated in elderly compared to younger individuals. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy."],"pediatric_use":["Pediatric Use Pediatric doses must be individualized (see DOSAGE AND ADMINISTRATION )."],"effective_time":"20250131","nursing_mothers":["Nursing Mothers Caution should be exercised when ergocalciferol is administered to a nursing woman. In a mother given large doses of vitamin D, 25-hydroxycholecalciferol appeared in the milk and caused hypercalcemia in her child. Monitoring of the infant's serum calcium concentration is required in that case (Goldberg, 1972)."],"adverse_reactions":["ADVERSE REACTIONS Hypervitaminosis D is characterized by effects on the following organ system: Renal: Impairment of renal function with polyuria, nocturia, polydipsia, hypercalciuria, reversible azotemia, hypertension, nephrocalcinosis, generalized vascular calcification, or irreversible renal insufficiency which may result in death. CNS: Mental retardation. Soft Tissues: Widespread calcification of the soft tissues, including the heart, blood vessels, renal tubules, and lungs. Skeletal: Bone demineralization (osteoporosis) in adults occurs concomitantly. Decline in the average rate of linear growth and increased mineralization of bones in infants and children (dwarfism), vague aches, stiffness, and weakness. Gastrointestinal: Nausea, anorexia, constipation. Metabolic: Mild acidosis, anemia, weight loss. To report SUSPECTED ADVERSE REACTIONS, contact Bionpharma Inc. at 1-888-235-2466 or FDA at 1-800-FDA-1088 or www.fda.gov/ medwatch."],"contraindications":["CONTRAINDICATIONS Ergocalciferol is contraindicated in patients with hypercalcemia, malabsorption syndrome, abnormal sensitivity to the toxic effects of vitamin D, and hypervitaminosis D."],"drug_interactions":["Drug Interactions Mineral oil interferes with the absorption of fat-soluble vitamins, including vitamin D preparations. Administration of thiazide diuretics to hypoparathyroid patients who are concurrently being treated with ergocalciferol may cause hypercalcemia."],"general_precautions":["General Vitamin D administration from fortified foods, dietary supplements, self-administered and prescription drug sources should be evaluated. Therapeutic dosage should be readjusted as soon as there is clinical improvement. Dosage levels must be individualized and great care exercised to prevent serious toxic effects. IN VITAMIN D RESISTANT RICKETS THE RANGE BETWEEN THERAPEUTIC AND TOXIC DOSES IS NARROW. When high therapeutic doses are used progress should be followed with frequent blood calcium determinations. In the treatment of hypoparathyroidism, intravenous calcium, parathyroid hormone, and/or dihydrotachysterol may be required. Maintenance of a normal serum phosphorous level by dietary phosphate restriction and/or administration of aluminum gels as intestinal phosphate binders in those patients with hyperphosphatemia as frequently seen in renal osteodystrophy is essential to prevent metastatis calcification. Adequate dietary calcium is necessary for clinical response to vitamin D therapy. Protect from light."],"clinical_pharmacology":["CLINICAL PHARMACOLOGY The in vivo synthesis of the major biologically active metabolites of vitamin D occurs in two steps. The first hydroxylation of ergocalciferol takes place in the liver (to 25-hydroxyvitamin D) and the second in the kidneys (to 1,25-dihydroxyvitamin D). Vitamin D metabolites promote the active absorption of calcium and phosphorous by the small intestine, thus elevating serum calcium and phosphate levels sufficiently to permit bone mineralization. Vitamin D metabolites also mobilize calcium and phosphate from bone and probably increase the reabsorption of calcium and perhaps also of phosphate by the renal tubules. There is a time lag of 10 to 24 hours between the administration of vitamin D and the initiation of its action in the body due to the necessity of synthesis of the active metabolites in the liver and kidneys. Parathyroid hormone is responsible for the regulation of this metabolism in the kidneys."],"indications_and_usage":["INDICATIONS AND USAGE Ergocalciferol is indicated for use in the treatment of hypoparathyroidism, refractory rickets, also known as vitamin D resistant rickets, and familial hypophosphatemia."],"spl_unclassified_section":["Rx only"],"dosage_and_administration":["DOSAGE AND ADMINISTRATION THE RANGE BETWEEN THERAPEUTIC AND TOXIC DOSES IS NARROW. Vitamin D Resistant Rickets: 12,000 to 500,000 USP units daily. Hypoparathyroidism: 50,000 to 200,000 USP units daily concomitantly with calcium lactate 4 g, six times per day. DOSAGE MUST BE INDIVIDUALIZED UNDER CLOSE MEDICAL SUPERVISION. Calcium intake should be adequate. Blood calcium and phosphorous determinations must be made every 2 weeks or more frequently if necessary. X-rays of the bones should be taken every month until condition is corrected and stabilized."],"spl_product_data_elements":["Ergocalciferol Ergocalciferol SOYBEAN OIL GELATIN, UNSPECIFIED GLYCERIN WATER D&C YELLOW NO. 10 FD&C BLUE NO. 1 ERGOCALCIFEROL ERGOCALCIFEROL PA140 Structure Formula"],"package_label_principal_display_panel":["Vitamin D (Ergocalciferol Capsules, USP) 1,250 mcg 50,000 USP Units Label"],"carcinogenesis_and_mutagenesis_and_impairment_of_fertility":["Carcinogenesis, Mutagenesis, Impairment of Fertility No long-term animal studies have been performed to evaluate the drug's potential in these areas."]},"tags":[{"label":"Provitamin D2 Compound","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"25-hydroxyvitamin D-1 alpha hydroxylase, mitochondrial","category":"target"},{"label":"CYP27B1","category":"gene"},{"label":"CYP2R1","category":"gene"},{"label":"VDR","category":"gene"},{"label":"A11CC01","category":"atc"},{"label":"Oral","category":"route"},{"label":"Intravenous","category":"route"},{"label":"Capsule","category":"form"},{"label":"Emulsion","category":"form"},{"label":"Off-Patent","category":"patent"},{"label":"Generic Available","category":"availability"},{"label":"Established","category":"status"},{"label":"Familial x-linked hypophosphatemic vitamin D refractory rickets","category":"indication"},{"label":"Glucocorticoid Induced Osteoporosis","category":"indication"},{"label":"Hyperparathyroidism Secondary to Chronic Renal Failure with Dialysis","category":"indication"},{"label":"Hypocalcemia","category":"indication"},{"label":"Hypogonadal Osteoporosis in Males","category":"indication"},{"label":"Hypoparathyroidism","category":"indication"},{"label":"Esjay Pharma","category":"company"},{"label":"Approved 1940s","category":"decade"},{"label":"Bone Density Conservation Agents","category":"pharmacology"},{"label":"Calcium-Regulating Hormones and Agents","category":"pharmacology"},{"label":"Micronutrients","category":"pharmacology"},{"label":"Vitamins","category":"pharmacology"}],"phase":"marketed","safety":{"boxedWarnings":[],"safetySignals":[{"date":"","signal":"FATIGUE","source":"FDA FAERS","actionTaken":"36308 reports"},{"date":"","signal":"NAUSEA","source":"FDA FAERS","actionTaken":"27024 reports"},{"date":"","signal":"DIARRHOEA","source":"FDA FAERS","actionTaken":"25822 reports"},{"date":"","signal":"HEADACHE","source":"FDA FAERS","actionTaken":"24770 reports"},{"date":"","signal":"DRUG INEFFECTIVE","source":"FDA FAERS","actionTaken":"24588 reports"},{"date":"","signal":"PAIN","source":"FDA FAERS","actionTaken":"23208 reports"},{"date":"","signal":"OFF LABEL USE","source":"FDA FAERS","actionTaken":"21944 reports"},{"date":"","signal":"DYSPNOEA","source":"FDA FAERS","actionTaken":"19352 reports"},{"date":"","signal":"ARTHRALGIA","source":"FDA FAERS","actionTaken":"19247 reports"},{"date":"","signal":"DIZZINESS","source":"FDA FAERS","actionTaken":"18670 reports"}],"commonSideEffects":[{"effect":"Irreversible renal insufficiency","drugRate":"reported","severity":"unknown"},{"effect":"Hypertension","drugRate":"reported","severity":"unknown"},{"effect":"Nephrocalcinosis","drugRate":"reported","severity":"unknown"},{"effect":"Generalized vascular calcification","drugRate":"reported","severity":"unknown"},{"effect":"Mental retardation","drugRate":"reported","severity":"unknown"},{"effect":"Widespread calcification of the soft tissues","drugRate":"reported","severity":"unknown"},{"effect":"Bone demineralization (osteoporosis)","drugRate":"reported","severity":"unknown"},{"effect":"Dwarfism","drugRate":"reported","severity":"unknown"},{"effect":"Vague aches","drugRate":"reported","severity":"unknown"},{"effect":"Stiffness","drugRate":"reported","severity":"unknown"},{"effect":"Weakness","drugRate":"reported","severity":"unknown"},{"effect":"Nausea","drugRate":"reported","severity":"unknown"},{"effect":"Anorexia","drugRate":"reported","severity":"unknown"},{"effect":"Constipation","drugRate":"reported","severity":"unknown"},{"effect":"Mild acidosis","drugRate":"reported","severity":"unknown"},{"effect":"Anemia","drugRate":"reported","severity":"unknown"},{"effect":"Weight loss","drugRate":"reported","severity":"unknown"},{"effect":"Polyuria","drugRate":"reported","severity":"unknown"},{"effect":"Nocturia","drugRate":"reported","severity":"unknown"},{"effect":"Polydipsia","drugRate":"reported","severity":"unknown"},{"effect":"Hypercalciuria","drugRate":"reported","severity":"unknown"},{"effect":"Reversible azotemia","drugRate":"reported","severity":"unknown"}],"contraindications":["Achalasia of esophagus","Acute nephropathy","Acute peptic ulcer","Anemia due to enzyme deficiency","Arteriosclerosis obliterans","Aseptic necrosis of bone of jaw","Atrial fibrillation","Bed-ridden","Blood coagulation disorder","Carcinoma of female breast","Central nervous system depression","Constipation","Dehydration","Dental fluorosis","Diabetes mellitus","Diarrhea","Disease of liver","Duodenitis","Dysphagia","Esophageal Obstruction","Esophageal dysmotility","Esophagitis","Fracture of femur","Gastritis","Hb SS disease"],"specialPopulations":{"Pregnancy":"Pregnancy Category CAnimal reproduction studies have shown fetal abnormalities in several species associated with hypervitaminosis D. These are similar to the supravalvular aortic stenosis syndrome described in infants by Black in England (1963). This syndrome was characterized by supravalvular aortic stenosis, elfin facies, and mental retardation. For the protection of the fetus, therefore, the use of vitamin in excess of the recommended dietary allowance during normal pregnancy should be avoided.","Geriatric use":"Clinical studies of ergocalciferol did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients. few published reports have suggested that the absorption of orally administered vitamin may be attenuated in elderly compared to younger, individuals. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy in this population.","Paediatric use":"Pediatric doses must be individualized see DOSAGE AND ADMINISTRATION"}},"trials":[],"aliases":[],"company":"Esjay Pharma","patents":[],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=ERGOCALCIFEROL","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T00:41:22.279950+00:00"},"timeline":{"url":"https://en.wikipedia.org/wiki/Ergocalciferol","method":"deterministic","source":"Wikipedia","rawText":"","confidence":0.8,"sourceType":"wikipedia","retrievedAt":"2026-04-20T00:41:30.450854+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T00:41:28.951162+00:00"},"regulatory.us":{"url":"","method":"api_direct","source":"FDA Drugs@FDA","rawText":"","confidence":1,"sourceType":"fda_drugsfda","retrievedAt":"2026-04-20T00:41:21.400297+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=ERGOCALCIFEROL","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T00:41:29.387622+00:00"},"mechanism.drugClass":{"url":"https://api.fda.gov/drug/label.json","method":"deterministic","source":"FDA Label (EPC)","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T00:41:17.786631+00:00"},"administration.route":{"url":"","method":"deterministic","source":"FDA Label","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T00:41:17.786657+00:00"},"safety.boxedWarnings":{"url":"","method":"deterministic","source":"FDA Label (no boxed warning)","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T00:41:17.786662+00:00"},"safety.safetySignals":{"url":"https://api.fda.gov/drug/event.json","method":"api_direct","source":"FDA FAERS","rawText":"","confidence":1,"sourceType":"fda_faers","retrievedAt":"2026-04-20T00:41:30.975371+00:00"},"mechanism.target_chembl":{"url":"","method":"api_direct","source":"ChEMBL mechanism: Vitamin D receptor agonist","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T00:41:30.450784+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL1536/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T00:41:30.106973+00:00"},"regulatory.fda_application":{"url":"","method":"deterministic","source":"FDA Label","rawText":"ANDA080704","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T00:41:17.786664+00:00"}},"allNames":"drisdol","offLabel":[],"synonyms":["ergocalciferol","vitamin D2","calciferol","ercalciol","ergorone"],"timeline":[{"date":"1941-01-01","type":"neutral","source":"FDA Orange Book","milestone":"Rights transferred from SANOFI AVENTIS US to Esjay Pharma"}],"aiSummary":"Drisdol (Ergocalciferol) is a provitamin D2 compound developed by Sanofi Aventis US and currently owned by Esjay Pharma. It targets the 25-hydroxyvitamin D-1 alpha hydroxylase enzyme and is used to treat various bone disorders, including rickets, osteoporosis, and hypocalcemia. Drisdol is a small molecule modality that has been FDA-approved since 1941 and is now available as a generic medication. It is used to treat a range of conditions, including familial x-linked hypophosphatemic vitamin D refractory rickets, glucocorticoid-induced osteoporosis, and hyperparathyroidism secondary to chronic renal failure. Drisdol is off-patent and has multiple generic manufacturers.","approvals":[{"date":"1941-01-11","orphan":false,"company":"SANOFI AVENTIS US","regulator":"FDA"}],"brandName":"Drisdol","ecosystem":[{"indication":"Familial x-linked hypophosphatemic vitamin D refractory rickets","otherDrugs":[{"name":"burosumab","slug":"burosumab","company":"Ultragenyx Pharm Inc"}],"globalPrevalence":null},{"indication":"Glucocorticoid Induced Osteoporosis","otherDrugs":[{"name":"alendronic acid","slug":"alendronic-acid","company":"Merck And Co Inc"},{"name":"colecalciferol","slug":"colecalciferol","company":"Sandoz"},{"name":"risedronic acid","slug":"risedronic-acid","company":"Warner Chilcott Llc"},{"name":"teriparatide","slug":"teriparatide","company":"Lilly"}],"globalPrevalence":200000000},{"indication":"Hyperparathyroidism Secondary to Chronic Renal Failure with Dialysis","otherDrugs":[{"name":"cinacalcet","slug":"cinacalcet","company":"Amgen"},{"name":"doxercalciferol","slug":"doxercalciferol","company":"Genzyme Corp"}],"globalPrevalence":null},{"indication":"Hypocalcemia","otherDrugs":[{"name":"calcifediol","slug":"calcifediol","company":""},{"name":"calcitriol","slug":"calcitriol","company":"Validus Pharms"},{"name":"calcium acetate","slug":"calcium-acetate","company":"B Braun"},{"name":"calcium carbonate","slug":"calcium-carbonate","company":"Mcneil Cons"}],"globalPrevalence":null},{"indication":"Hypogonadal Osteoporosis in Males","otherDrugs":[{"name":"alendronic acid","slug":"alendronic-acid","company":"Merck And Co Inc"},{"name":"colecalciferol","slug":"colecalciferol","company":"Sandoz"},{"name":"teriparatide","slug":"teriparatide","company":"Lilly"},{"name":"zoledronic acid","slug":"zoledronic-acid","company":"Novartis"}],"globalPrevalence":200000000},{"indication":"Hypoparathyroidism","otherDrugs":[{"name":"calcitriol","slug":"calcitriol","company":"Validus Pharms"},{"name":"colecalciferol","slug":"colecalciferol","company":"Sandoz"},{"name":"parathyroid hormone","slug":"parathyroid-hormone","company":"Nps Pharms Inc"}],"globalPrevalence":null},{"indication":"Osteomalacia","otherDrugs":[{"name":"burosumab","slug":"burosumab","company":"Ultragenyx Pharm Inc"},{"name":"colecalciferol","slug":"colecalciferol","company":"Sandoz"}],"globalPrevalence":56000},{"indication":"Osteoporosis","otherDrugs":[{"name":"abaloparatide","slug":"abaloparatide","company":"Radius Health Inc"},{"name":"calcium citrate","slug":"calcium-citrate","company":""},{"name":"calcium gluconate","slug":"calcium-gluconate","company":""},{"name":"calcium phosphate","slug":"calcium-phosphate","company":""}],"globalPrevalence":200000000}],"mechanism":{"target":"25-hydroxyvitamin D-1 alpha hydroxylase, mitochondrial","novelty":"First-in-class","targets":[{"gene":"CYP27B1","source":"DrugCentral","target":"25-hydroxyvitamin D-1 alpha hydroxylase, mitochondrial","protein":"25-hydroxyvitamin D-1 alpha hydroxylase, mitochondrial"},{"gene":"CYP2R1","source":"DrugCentral","target":"Vitamin D 25-hydroxylase","protein":"Vitamin D 25-hydroxylase"},{"gene":"VDR","source":"DrugCentral","target":"Vitamin D3 receptor","protein":"Vitamin D3 receptor"}],"modality":"Small Molecule","drugClass":"Provitamin D2 Compound [EPC]","explanation":"","oneSentence":"","technicalDetail":"Drisdol (Ergocalciferol) is a vitamin D2 analog that is converted to its active form, calcitriol, through hydroxylation in the liver and kidneys. Calcitriol then acts as a ligand for the vitamin D receptor, which regulates the expression of genes involved in calcium homeostasis and bone metabolism."},"_wikipedia":{"url":"https://en.wikipedia.org/wiki/Ergocalciferol","title":"Ergocalciferol","extract":"Ergocalciferol, also known as vitamin D2 and nonspecifically calciferol, is a type of vitamin D found in food. It is used as a dietary supplement to prevent and treat vitamin D deficiency due to poor absorption by the intestines or liver disease. It may also be used for low blood calcium due to hypoparathyroidism. It is taken by mouth or via injection into a muscle."},"commercial":{"launchDate":"1941","_launchSource":"DrugCentral (FDA 1941-01-11, SANOFI AVENTIS US)"},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/2838","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=ERGOCALCIFEROL","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=ERGOCALCIFEROL","fields":["publications"],"source":"PubMed/NCBI"},{"id":4,"url":"https://en.wikipedia.org/wiki/Ergocalciferol","fields":["history","overview"],"source":"Wikipedia"},{"id":5,"url":"https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book-data-files","fields":["patents","exclusivity","genericManufacturers"],"source":"FDA Orange Book"}],"_enrichedAt":"2026-03-30T11:05:52.213917","_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T00:41:33.495317+00:00","fieldsConflicting":1,"overallConfidence":0.8},"biosimilars":[],"competitors":[{"drugName":"calcitriol","drugSlug":"calcitriol","fdaApproval":"1978-08-17","genericCount":18,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"colecalciferol","drugSlug":"colecalciferol","fdaApproval":"2000-05-18","relationship":"same-class"},{"drugName":"calcifediol","drugSlug":"calcifediol","fdaApproval":"1980-08-05","patentExpiry":"Sep 7, 2030","patentStatus":"Patent protected","relationship":"same-class"}],"genericName":"ergocalciferol","indications":{"approved":[{"name":"Familial x-linked hypophosphatemic vitamin D refractory rickets","source":"DrugCentral","snomedId":82236004,"regulator":"FDA"},{"name":"Glucocorticoid Induced Osteoporosis","source":"DrugCentral","snomedId":"","regulator":"FDA","eligibility":null,"usPrevalence":10000000,"globalPrevalence":200000000,"prevalenceMethod":"curated","prevalenceSource":"IOF, 2023"},{"name":"Hyperparathyroidism Secondary to Chronic Renal Failure with Dialysis","source":"DrugCentral","snomedId":"","regulator":"FDA","eligibility":null},{"name":"Hypocalcemia","source":"DrugCentral","snomedId":5291005,"regulator":"FDA","eligibility":null},{"name":"Hypogonadal Osteoporosis in Males","source":"DrugCentral","snomedId":"","regulator":"FDA","eligibility":null,"usPrevalence":10000000,"globalPrevalence":200000000,"prevalenceMethod":"curated","prevalenceSource":"IOF, 2023"},{"name":"Hypoparathyroidism","source":"DrugCentral","snomedId":36976004,"regulator":"FDA","eligibility":"Adults and children with hypoparathyroidism"},{"name":"Osteomalacia","source":"DrugCentral","snomedId":4598005,"regulator":"FDA","eligibility":null,"prevalenceClass":"1-9 / 1 000 000","globalPrevalence":56000,"prevalenceMethod":"orphanet","prevalenceSource":"Orphanet (33818653[PMID]_ORPHANET)"},{"name":"Osteoporosis","source":"DrugCentral","snomedId":64859006,"regulator":"FDA","eligibility":null,"usPrevalence":10000000,"globalPrevalence":200000000,"prevalenceMethod":"curated","prevalenceSource":"IOF, 2023"},{"name":"Postmenopausal osteoporosis","source":"DrugCentral","snomedId":102447009,"regulator":"FDA","eligibility":null,"usPrevalence":10000000,"globalPrevalence":200000000,"prevalenceMethod":"curated","prevalenceSource":"IOF, 2023"},{"name":"Prevention of dental caries","source":"DrugCentral","snomedId":426482000,"regulator":"FDA","eligibility":null},{"name":"Rickets","source":"DrugCentral","snomedId":41345002,"regulator":"FDA"},{"name":"Vitamin D Dependent Rickets","source":"DrugCentral","snomedId":"","regulator":"FDA"},{"name":"Vitamin D deficiency","source":"DrugCentral","snomedId":34713006,"regulator":"FDA"},{"name":"Vitamin Deficiency Prevention","source":"DrugCentral","snomedId":"","regulator":"FDA"},{"name":"Vitamin deficiency","source":"DrugCentral","snomedId":85670002,"regulator":"FDA"}],"offLabel":[{"name":"Anticonvulsant-induced Osteomalacia","source":"DrugCentral","drugName":"ERGOCALCIFEROL","evidenceCount":1,"evidenceLevel":"emerging"},{"name":"Hyperparathyroidism Secondary to Chronic Renal Failure","source":"DrugCentral","drugName":"ERGOCALCIFEROL","evidenceCount":150,"evidenceLevel":"strong"},{"name":"Renal osteodystrophy","source":"DrugCentral","drugName":"ERGOCALCIFEROL","evidenceCount":119,"evidenceLevel":"strong"}],"pipeline":[]},"currentOwner":"Esjay Pharma","drugCategory":"established","labelChanges":[],"patentStatus":"Off-patent — no active Orange Book patents","relatedDrugs":[{"drugId":"calcitriol","brandName":"calcitriol","genericName":"calcitriol","approvalYear":"1978","relationship":"same-class"},{"drugId":"colecalciferol","brandName":"colecalciferol","genericName":"colecalciferol","approvalYear":"2000","relationship":"same-class"},{"drugId":"calcifediol","brandName":"calcifediol","genericName":"calcifediol","approvalYear":"1980","relationship":"same-class"}],"trialDetails":[{"nctId":"NCT06969716","phase":"","title":"Frequency of Fibromyalgia Syndrome in Elderly Patients Aged 80 and Above and Its Relationship With Geriatric Parameters","status":"COMPLETED","sponsor":"Sultan 1. Murat State Hospital","startDate":"2025-05-01","conditions":["Fibromyalgia","Old Age; Debility"],"enrollment":420,"completionDate":"2026-03-03"},{"nctId":"NCT05619289","phase":"PHASE2","title":"Immune Mechanisms of Vitamin D to Reduce Chronic Pain After Burn","status":"COMPLETED","sponsor":"University of North Carolina, Chapel Hill","startDate":"2023-04-12","conditions":["Burn Injury","Chronic Pain"],"enrollment":40,"completionDate":"2026-01-16"},{"nctId":"NCT07369063","phase":"PHASE2","title":"Impact of Vitamin D Therapy on Thyroid Function and Antibody Levels in Pediatric Graves' Disease","status":"RECRUITING","sponsor":"Northwell Health","startDate":"2025-08-01","conditions":["Graves Disease","Graves' Disease","Hyperthyroidism"],"enrollment":30,"completionDate":"2027-02-28"},{"nctId":"NCT07366450","phase":"NA","title":"High-Dose vs Standard Ergocalciferol for Vitamin D Normalization in Aggressive Non-Hodgkin Lymphoma","status":"NOT_YET_RECRUITING","sponsor":"Phramongkutklao College of Medicine and Hospital","startDate":"2026-02-01","conditions":["Vitamin D 25-Hydroxylase Deficiency","Lymphoma Non-Hodgkin"],"enrollment":52,"completionDate":"2029-07-31"},{"nctId":"NCT03621553","phase":"PHASE4","title":"Vitamin D Homeostasis in Sarcoidosis","status":"RECRUITING","sponsor":"University of Texas Southwestern Medical Center","startDate":"2010-07-01","conditions":["Sarcoidosis","Vitamin D Insufficiency"],"enrollment":90,"completionDate":"2026-12-30"},{"nctId":"NCT05084248","phase":"PHASE4","title":"Vitamin D Deficiency in Adults Following a Major Burn Injury","status":"COMPLETED","sponsor":"University of Texas Southwestern Medical Center","startDate":"2022-09-29","conditions":["Vitamin D Deficiency","Burns"],"enrollment":48,"completionDate":"2025-08-18"},{"nctId":"NCT05259527","phase":"PHASE2","title":"Vitamin D Supplementation on Reported Rates of Taxane-Induced Neuropathy","status":"RECRUITING","sponsor":"Virginia Commonwealth University","startDate":"2022-12-19","conditions":["Neuropathic Pain"],"enrollment":120,"completionDate":"2030-03-31"},{"nctId":"NCT07200804","phase":"","title":"Relationship Between Serum Vitamin D and Atherosclerosis in Hemodialysis Patients","status":"COMPLETED","sponsor":"Ain Shams University","startDate":"2021-06-01","conditions":["Serum","Vitamin D","Atherosclerosis","Hemodialysis"],"enrollment":90,"completionDate":"2021-12-01"},{"nctId":"NCT05016310","phase":"NA","title":"A Study of High-Dose Vit D Versus Standard of Care Vit D Supplementation","status":"COMPLETED","sponsor":"Wake Forest University Health Sciences","startDate":"2021-09-16","conditions":["Breast","Breast Cancer","Osteoporosis"],"enrollment":7,"completionDate":"2024-08-15"},{"nctId":"NCT00424619","phase":"PHASE4","title":"A Randomised, Controlled Comparison of Vitamin D Strategies is Acute Hip Fracture Patients","status":"COMPLETED","sponsor":"McMaster University","startDate":"2007-10","conditions":["Hip Fracture"],"enrollment":64,"completionDate":"2009-07"},{"nctId":"NCT06283615","phase":"NA","title":"Effect of Vitamin D on Skeletal Muscle Function and Qol in Patients With Chronic Intestinal Failure/Insufficiency","status":"COMPLETED","sponsor":"Jinling Hospital, China","startDate":"2024-03-12","conditions":["Intestinal Failure"],"enrollment":84,"completionDate":"2025-03-30"},{"nctId":"NCT05458024","phase":"PHASE2","title":"Vitamin D to ENhance TraUma REcovery","status":"COMPLETED","sponsor":"University of North Carolina, Chapel Hill","startDate":"2023-01-24","conditions":["Musculoskeletal Pain"],"enrollment":71,"completionDate":"2024-05-01"},{"nctId":"NCT06642441","phase":"NA","title":"Effect of Vitamin D Supplementation on Chemotherapy Side Effects After Adjuvant Chemotherapy for Breast Cancer","status":"RECRUITING","sponsor":"Jiuda Zhao","startDate":"2024-12-01","conditions":["Vitamin D","Chemotherapy","Breast Cancer","Adverse Reaction"],"enrollment":100,"completionDate":"2026-04-30"},{"nctId":"NCT06642428","phase":"NA","title":"Effect of Vitamin D Supplementation on the Efficacy and Adverse Effects of Neoadjuvant Therapy in Patients with Breast Cancer","status":"RECRUITING","sponsor":"Jiuda Zhao","startDate":"2024-10-18","conditions":["Vitamin D","Neoadjuvant Therapy","Breast Cancer","Adverse Reaction","Efficacy","Chemotherapy"],"enrollment":140,"completionDate":"2026-04-30"},{"nctId":"NCT03133195","phase":"PHASE3","title":"The Effect of Teriparatide on Bone Union in Unstable Intertrochanteric Fracture Patients Treated With PFNA","status":"COMPLETED","sponsor":"King Chulalongkorn Memorial Hospital","startDate":"2017-05-17","conditions":["Unstable Intertrochanteric Fracture","Pertrochanteric Fracture of Femur, Closed"],"enrollment":50,"completionDate":"2023-07-01"},{"nctId":"NCT04909931","phase":"NA","title":"Vitamin D Supplementation on Outcome and Disease Activity.","status":"COMPLETED","sponsor":"Department of Medical Services Ministry of Public Health of Thailand","startDate":"2021-05-01","conditions":["Rheumatoid Arthritis, Vitamin D , Disease Activity, DAS28ESR"],"enrollment":60,"completionDate":"2022-12-01"},{"nctId":"NCT05260255","phase":"NA","title":"Effect of Vitamin D Supplement on Disease Activity in SLE","status":"COMPLETED","sponsor":"Department of Medical Services Ministry of Public Health of Thailand","startDate":"2021-06-15","conditions":["Vitamin D Deficiency","Hypocalcemia","Hyperparathyroidism","Systemic Lupus Erythematosus (Disorder)"],"enrollment":100,"completionDate":"2022-12-01"},{"nctId":"NCT03743922","phase":"NA","title":"The Effects of Vitamin D2 Supplement During Pregnancy","status":"COMPLETED","sponsor":"Department of Medical Services Ministry of Public Health of Thailand","startDate":"2018-11-01","conditions":["Pregnancy Early"],"enrollment":60,"completionDate":"2020-05-30"},{"nctId":"NCT06650293","phase":"NA","title":"Effect of Vitamin D Supplementation as Adjuvant Therapy in Neonatal Jaundice in Combination With Phototherapy","status":"COMPLETED","sponsor":"Muhammad Aamir Latif","startDate":"2022-05-10","conditions":["Neonatal Jaundice"],"enrollment":100,"completionDate":"2022-11-10"},{"nctId":"NCT01321905","phase":"NA","title":"Prospective Intervention Study on Vitamin D in Patients With Cystic Fibrosis","status":"COMPLETED","sponsor":"Karolinska Institutet","startDate":"2010-04","conditions":["Cystic Fibrosis"],"enrollment":16,"completionDate":"2011-07"},{"nctId":"NCT05873933","phase":"NA","title":"An Investigation of a Multi-Function Skincare Product to Improve Aging, Eczema, and Acne Outcomes","status":"WITHDRAWN","sponsor":"Hemptress","startDate":"2024-07-01","conditions":["Acne","Eczema","Skin Aging"],"enrollment":0,"completionDate":"2024-11-01"},{"nctId":"NCT06618365","phase":"NA","title":"Oral or Intra Muscular Vitamin D2 Vs Oral or Intra Muscular Vitamin D3 in Treatment of Vitamin D Deficiency","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hamad Medical Corporation","startDate":"2023-02-02","conditions":["Vitamin D Deficiency"],"enrollment":100,"completionDate":"2025-12"},{"nctId":"NCT04983017","phase":"NA","title":"2021 PMT iAge® Intervention Trial by Edifice Health","status":"TERMINATED","sponsor":"Edifice Health","startDate":"2021-08-10","conditions":["Chronic Inflammation","Inflammaging"],"enrollment":781,"completionDate":"2022-09-09"},{"nctId":"NCT05313477","phase":"PHASE4","title":"The Effects of Vitamin D and Calcium Supplementation to Parathyroid Hormone in CHB Patients Treated With TDF","status":"COMPLETED","sponsor":"Mahidol University","startDate":"2022-05-01","conditions":["Parathyroid Hormone","Tenofovir Disoproxil Fumarate","Chronic Hepatitis B Virus","Vitamin D"],"enrollment":64,"completionDate":"2023-11-30"},{"nctId":"NCT05937789","phase":"NA","title":"Early Vitamin D3 Supplementation for Critically Ill Patients","status":"RECRUITING","sponsor":"National Taiwan University Hospital","startDate":"2024-01-22","conditions":["Vitamin D Deficiency","Critical Illness"],"enrollment":240,"completionDate":"2026-12-31"},{"nctId":"NCT05559112","phase":"NA","title":"Effects of Vitamin D-Enriched Mushrooms on Vitamin D Status and Immune Function and Inflammatory Status in Adults","status":"COMPLETED","sponsor":"Purdue University","startDate":"2022-12-05","conditions":["Vitamin D Deficiency"],"enrollment":36,"completionDate":"2024-04-30"},{"nctId":"NCT03046927","phase":"PHASE2,PHASE3","title":"Vitamin D and Residual Beta-Cell Function in Type 1 Diabetes","status":"COMPLETED","sponsor":"Benjamin U. Nwosu, MD","startDate":"2017-10-19","conditions":["Type 1 Diabetes"],"enrollment":48,"completionDate":"2021-04-20"},{"nctId":"NCT04450199","phase":"EARLY_PHASE1","title":"Does Supplementing Vitamin D Deficiency Affect Fusion Healing Rates in Elective Foot and Ankle Surgery?","status":"COMPLETED","sponsor":"Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)","startDate":"2020-07-24","conditions":["Vitamin D Deficiency"],"enrollment":25,"completionDate":"2024-03-11"},{"nctId":"NCT06018740","phase":"NA","title":"A Study to Examine the Effects of a Daily Supplement on Common Symptoms of Perimenopause and Menopause","status":"COMPLETED","sponsor":"Hologram Sciences","startDate":"2023-08-14","conditions":["Menopause","Perimenopause"],"enrollment":40,"completionDate":"2023-11-13"},{"nctId":"NCT02074631","phase":"PHASE2","title":"Prevention of Bone Loss After Pediatric Hematopoietic Cell Transplantation","status":"COMPLETED","sponsor":"Masonic Cancer Center, University of Minnesota","startDate":"2015-02","conditions":["Osteopenia","Osteoporosis"],"enrollment":63,"completionDate":"2022-10-06"},{"nctId":"NCT05434377","phase":"NA","title":"A Study of Fixed Dose Versus Serum Level-Based Titration Regimen of Vitamin D Supplementation in Dialysis Patients","status":"COMPLETED","sponsor":"Chulalongkorn University","startDate":"2022-08-01","conditions":["Vitamin D Deficiency","End Stage Renal Disease"],"enrollment":78,"completionDate":"2023-12-31"},{"nctId":"NCT04967469","phase":"NA","title":"Comparison of Serum Calcium Level Between Preoperative Vitamin D and Non-vitamin D Regimen of Total Parathyroidectomy in End-stage Renal Failure Patients in Rajavithi Hospital","status":"COMPLETED","sponsor":"Department of Medical Services Ministry of Public Health of Thailand","startDate":"2020-09-01","conditions":["End Stage Renal Disease"],"enrollment":60,"completionDate":"2023-12-30"},{"nctId":"NCT06176157","phase":"PHASE4","title":"Vitamin D Supplementation in Pediatrics. Oral or Parenteral! D2 or D3","status":"UNKNOWN","sponsor":"Ain Shams University","startDate":"2023-12","conditions":["Vitamin D Deficiency"],"enrollment":120,"completionDate":"2024-04"},{"nctId":"NCT01930539","phase":"NA","title":"Treatment of Vitamin D Deficiency in Intestinal Rehabilitation Clinic Patients With a Portable Ultraviolet B Lamp","status":"COMPLETED","sponsor":"University of Nebraska","startDate":"2013-09-16","conditions":["Vitamin D Deficiency","Short Bowel Syndrome"],"enrollment":11,"completionDate":"2015-12-01"},{"nctId":"NCT00204919","phase":"NA","title":"Vitamin D Administration in the Nursing Home","status":"COMPLETED","sponsor":"University of Wisconsin, Madison","startDate":"2001-06","conditions":["Vitamin D Deficiency","Osteoporosis"],"enrollment":96,"completionDate":"2004-11"},{"nctId":"NCT01029002","phase":"PHASE3","title":"The Effects of Vitamin D Repletion in Vitamin D Deficient Patients With Stage 3 and 4 Chronic Kidney Disease","status":"COMPLETED","sponsor":"Albert Einstein College of Medicine","startDate":"2009-10","conditions":["Chronic Renal Insufficiency","Proteinuria"],"enrollment":74,"completionDate":"2014-06"},{"nctId":"NCT00581828","phase":"PHASE4","title":"Does Treatment of Hypovitaminosis D Increase Calcium Absorption?","status":"COMPLETED","sponsor":"University of Wisconsin, Madison","startDate":"2005-01","conditions":["Osteoporosis","Osteopenia","Vitamin D Deficiency","Hypoparathyroidism","Hypercalciuria","Hypercalcemia"],"enrollment":19,"completionDate":"2008-12"},{"nctId":"NCT03499327","phase":"NA","title":"Human Intervention Study to Increase 25-hydroxyvitamin D Levels","status":"COMPLETED","sponsor":"University of Jena","startDate":"2018-03-05","conditions":["Vitamin D3 Deficiency"],"enrollment":50,"completionDate":"2018-04-30"},{"nctId":"NCT05733117","phase":"PHASE4","title":"Oral Nano Vitamin D Supplementation Efficacy in Inflammatory Bowel Disease","status":"UNKNOWN","sponsor":"Tomas Bata Hospital, Czech Republic","startDate":"2022-10-25","conditions":["Vitamin D Substitution"],"enrollment":120,"completionDate":"2024-01-01"},{"nctId":"NCT05549154","phase":"NA","title":"A Study on Prevention Strategies for CKD-SHPT and Related Complications Based on General Vitamin D Supplementation","status":"UNKNOWN","sponsor":"First Affiliated Hospital Xi'an Jiaotong University","startDate":"2022-12-05","conditions":["Chronic Kidney Disease 5D","Secondary Hyperparathyroidism Due to Renal Causes","Vitamin D Deficiency"],"enrollment":372,"completionDate":"2023-10-30"},{"nctId":"NCT05673980","phase":"NA","title":"Oral Vitamin D2 for Prevention of COVID-19","status":"UNKNOWN","sponsor":"Peking University Third Hospital","startDate":"2022-12-18","conditions":["Healthy Volunteers"],"enrollment":218,"completionDate":"2023-02-20"},{"nctId":"NCT04081818","phase":"NA","title":"A Study on the Effects of Nutritious Mushrooms in Adults With Metabolic Syndrome","status":"COMPLETED","sponsor":"Harokopio University","startDate":"2021-01-01","conditions":["Metabolic Syndrome"],"enrollment":100,"completionDate":"2022-03-16"},{"nctId":"NCT05142072","phase":"EARLY_PHASE1","title":"Design and Application of Vitamin D Films for Burn Healing After Cauterizing Surgery","status":"COMPLETED","sponsor":"Deraya University","startDate":"2021-12-18","conditions":["Nasal Obstruction"],"enrollment":20,"completionDate":"2022-02-20"},{"nctId":"NCT02889237","phase":"NA","title":"Fracture Healing Assessed by HR-pQCT After Administration of Calcium and Vitamin D","status":"COMPLETED","sponsor":"VieCuri Medical Centre","startDate":"2014-10","conditions":["Bone Fracture"],"enrollment":52,"completionDate":"2020-06-18"},{"nctId":"NCT04591847","phase":"PHASE3","title":"Pregnancy Outcome and Vitamin D Level Among Vitamin D Supplementation During Pregnancy","status":"COMPLETED","sponsor":"Department of Medical Services Ministry of Public Health of Thailand","startDate":"2020-10-19","conditions":["Pregnancy Outcome Among Vitamin D Supplementation During Pregnancy"],"enrollment":60,"completionDate":"2021-08-31"},{"nctId":"NCT00743574","phase":"NA","title":"Health Benefits of Vitamin D and Calcium in Women With PCOS (Polycystic Ovarian Syndrome)","status":"COMPLETED","sponsor":"Yale University","startDate":"2008-08","conditions":["Polycystic Ovarian Syndrome","Vitamin D Deficiency"],"enrollment":36,"completionDate":"2013-02"},{"nctId":"NCT01474486","phase":"NA","title":"Feasibility and Effectiveness of Micronutrients as Palliative Care Therapy in Patients With Congestive Heart Failure","status":"COMPLETED","sponsor":"Phoenix VA Health Care System","startDate":"2010-04","conditions":["Congestive Heart Failure","Ischemic Cardiomyopathy"],"enrollment":40,"completionDate":"2016-02"},{"nctId":"NCT01568255","phase":"PHASE4","title":"Is Treatment of Vitamin D Deficiency Associated With Resolution of Statin-Induced Muscular Symptoms","status":"COMPLETED","sponsor":"Cedars-Sinai Medical Center","startDate":"2012-03","conditions":["Myopathic Symptoms"],"enrollment":11,"completionDate":"2019-06"},{"nctId":"NCT04883203","phase":"PHASE3","title":"The Effect of Vitamin D Supplementation on COVID-19 Recovery","status":"COMPLETED","sponsor":"University of Monastir","startDate":"2020-04-22","conditions":["Covid19"],"enrollment":130,"completionDate":"2020-10-31"},{"nctId":"NCT04829487","phase":"NA","title":"The Role of Vitamin D Supplementation on Pain in Women With Primary Dysmenorrhea and Hypovitaminosis D","status":"UNKNOWN","sponsor":"Mahidol University","startDate":"2021-05-01","conditions":["Hypovitaminosis D"],"enrollment":36,"completionDate":"2023-04-30"},{"nctId":"NCT00502268","phase":"PHASE4","title":"Vitamin D and Carboxy PTH Fragments in Coronary Calcification","status":"WITHDRAWN","sponsor":"Southeast Renal Research Institute","startDate":"2008-02","conditions":["Coronary Calcification","Endstage Renal Disease","Parathyroid Hormone"],"enrollment":0,"completionDate":"2009-07"},{"nctId":"NCT03747523","phase":"EARLY_PHASE1","title":"Pilot Study: The Effect of Ergocalciferol on Plasma Mucin-1 Levels","status":"COMPLETED","sponsor":"Wake Forest University Health Sciences","startDate":"2019-03-12","conditions":["Ergocalciferol"],"enrollment":44,"completionDate":"2020-01-27"},{"nctId":"NCT02297568","phase":"NA","title":"Vitamin D Supplementation During Lactation","status":"COMPLETED","sponsor":"Department of Medical Services Ministry of Public Health of Thailand","startDate":"2014-03","conditions":["Deficiency, Vitamin D"],"enrollment":80,"completionDate":"2015-06"},{"nctId":"NCT02018133","phase":"","title":"Identification of Markers for Determining the Efficacy of Vitamin D Receptor Activator Therapy in Stage 3/4 CKD Patients","status":"COMPLETED","sponsor":"University of Illinois at Chicago","startDate":"2009-12","conditions":["CKD Stage 3/4"],"enrollment":8,"completionDate":"2012-06"},{"nctId":"NCT04472481","phase":"PHASE4","title":"Vitamin D Effect in Rheumatoid Arthritis.","status":"COMPLETED","sponsor":"Tanta University","startDate":"2019-09-06","conditions":["Active Rheumatoid Arthritis"],"enrollment":20,"completionDate":"2020-03-22"},{"nctId":"NCT03401541","phase":"EARLY_PHASE1","title":"25-Hydroxyvitamin D Pharmacokinetic Study","status":"COMPLETED","sponsor":"Boston University","startDate":"2018-10-01","conditions":["Vitamin D Deficiency","Fat Malabsorption"],"enrollment":16,"completionDate":"2019-11-01"},{"nctId":"NCT02352974","phase":"PHASE1","title":"GAD-Alum (Diamyd) Administered Into Lymph Nodes in Combination With Vitamin D in Type 1 Diabetes (DIAGNODE-1)","status":"COMPLETED","sponsor":"Johnny Ludvigsson","startDate":"2015-01","conditions":["Diabetes Mellitus, Type 1"],"enrollment":12,"completionDate":"2019-10"},{"nctId":"NCT01848236","phase":"NA","title":"Effects of Vitamin D Insufficiency in Man","status":"COMPLETED","sponsor":"University of California, Los Angeles","startDate":"2010-08","conditions":["Vitamin D Deficiency"],"enrollment":300,"completionDate":"2020-02"},{"nctId":"NCT00715429","phase":"NA","title":"Vitamin D for Painful Nocturnal Leg Cramps","status":"TERMINATED","sponsor":"University of Wisconsin, Madison","startDate":"2007-08","conditions":["Leg Cramps, Nocturnal"],"enrollment":29,"completionDate":"2011-08"},{"nctId":"NCT04091178","phase":"PHASE2","title":"Vitamin D Supplementation to Correct the Vitamin D Deficiency for Breast Cancer","status":"COMPLETED","sponsor":"Institut du Cancer de Montpellier - Val d'Aurelle","startDate":"2013-10-10","conditions":["Breast Cancer"],"enrollment":57,"completionDate":"2017-03-16"},{"nctId":"NCT02426840","phase":"PHASE3","title":"Calcium and High-dose Vitamin D Supplementation on Bone Mineral Density Among HIV-infected Children and Adolescents","status":"COMPLETED","sponsor":"Chiang Mai University","startDate":"2015-04","conditions":["Adverse Bone Health","HIV Infection"],"enrollment":200,"completionDate":"2019-02"},{"nctId":"NCT02752841","phase":"NA","title":"The Effect of Vitamin D Repletion on Kidney Stone Risk","status":"TERMINATED","sponsor":"Brown University","startDate":"2016-05-01","conditions":["Calculi"],"enrollment":20,"completionDate":"2019-05-31"},{"nctId":"NCT03066817","phase":"PHASE1,PHASE2","title":"Vitamin D and Bone Homeostasis in Ortho Polytrauma Patients","status":"SUSPENDED","sponsor":"New York City Health and Hospitals Corporation","startDate":"2017-07-01","conditions":["Vitamin D Deficiency","Polytrauma","Orthopedic Disorder"],"enrollment":60,"completionDate":"2020-03"},{"nctId":"NCT00538720","phase":"PHASE1","title":"Effects of Vitamin D Replacement in Patients With Primary Hyperparathyroidism (PHPT)","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2007-10","conditions":["Hyperparathyroidism"],"enrollment":22,"completionDate":"2018-05-30"},{"nctId":"NCT00288873","phase":"PHASE4","title":"Characterization of Hyperparathyroidism and Vitamin D Deficiency in Obesity","status":"COMPLETED","sponsor":"Weill Medical College of Cornell University","startDate":"2006-02","conditions":["Vitamin D Deficiency","Secondary Hyperparathyroidism","Obesity"],"enrollment":60,"completionDate":"2007-07"},{"nctId":"NCT01337635","phase":"NA","title":"Vitamin D Deficiency and Atopic Dermatitis","status":"TERMINATED","sponsor":"Medical College of Wisconsin","startDate":"2010-11","conditions":["Atopic Dermatitis","Vitamin D Deficiency"],"enrollment":7,"completionDate":"2013-04"},{"nctId":"NCT03035084","phase":"PHASE4","title":"Is Vitamin D2 Treatment-associated Decrease in 25(OH)D3 Level a Reciprocal Phenomena?","status":"COMPLETED","sponsor":"King Faisal Specialist Hospital & Research Center","startDate":"2017-02-15","conditions":["Vitamin D Deficiency","25-Hydroxyvitamin D Concentration"],"enrollment":100,"completionDate":"2017-11-20"},{"nctId":"NCT03603444","phase":"","title":"Reliability of Serum Calcium to Phosphorus (Ca/P) Ratio as an Accurate and Inexpensive Tool to Define Disorders of Ca-P Metabolism","status":"COMPLETED","sponsor":"Azienda Ospedaliero-Universitaria di Modena","startDate":"2011-01-01","conditions":["Phosphorus and Calcium Disorders"],"enrollment":606,"completionDate":"2018-01-01"},{"nctId":"NCT01601847","phase":"PHASE4","title":"Wheezing in Black Preterm Infants: Impact of Vitamin D Supplementation Strategy","status":"COMPLETED","sponsor":"Case Western Reserve University","startDate":"2013-01","conditions":["Wheezing","Allergy"],"enrollment":300,"completionDate":"2017-03-12"},{"nctId":"NCT03544671","phase":"NA","title":"Effect of Vitamin D3 Supplementation in Children From 12 to 30 Months of Age.","status":"COMPLETED","sponsor":"Instituto Nacional de Salud Publica, Mexico","startDate":"2016-09-15","conditions":["Vitamin D Deficiency","25-Hydroxyvitamin D3 Deficiency, Selective"],"enrollment":220,"completionDate":"2017-12-21"},{"nctId":"NCT00491322","phase":"NA","title":"Vitamin D Deficiency, Insulin Resistance and FGF-23","status":"COMPLETED","sponsor":"Massachusetts General Hospital","startDate":"2006-05","conditions":["Vitamin D Deficiency"],"enrollment":92,"completionDate":"2008-02"},{"nctId":"NCT00892099","phase":"NA","title":"DIVINE: Dialysis Infection and Vitamin D In New England","status":"COMPLETED","sponsor":"Massachusetts General Hospital","startDate":"2009-11","conditions":["End Stage Renal Disease"],"enrollment":105,"completionDate":"2014-10"},{"nctId":"NCT01971411","phase":"","title":"Vitamin D Deficiency in Elderly African American Women in Central Texas","status":"COMPLETED","sponsor":"McLennan County Medical Education and Research Foundation","startDate":"2006-03","conditions":["Vitamin D Deficiency","Osteoporosis","Osteopenia"],"enrollment":60,"completionDate":"2007-05"},{"nctId":"NCT01578473","phase":"PHASE1","title":"Testosterone Pellets Plus Vitamin D and E Versus Vitamin D and E Alone for the Treatment of Peyronie's Disease","status":"COMPLETED","sponsor":"Men's Health Boston","startDate":"2013-05-23","conditions":["Peyronie's Disease"],"enrollment":75,"completionDate":"2017-11-13"},{"nctId":"NCT03053414","phase":"NA","title":"Vitamin D Repletion and Maintenance in IBD: How Much and How Often","status":"WITHDRAWN","sponsor":"Cedars-Sinai Medical Center","startDate":"2017-02-20","conditions":["Inflammatory Bowel Diseases","Vitamin D Deficiency"],"enrollment":0,"completionDate":"2018-12-01"},{"nctId":"NCT03073369","phase":"PHASE4","title":"Effect of Ergocalciferol on Iron Metabolism in Individuals With Chronic Kidney Disease","status":"WITHDRAWN","sponsor":"University of Alabama at Birmingham","startDate":"2018-01-01","conditions":["CKD","Chronic Kidney Diseases","Hepcidin","Ergocalciferol","Vitamin D","Iron-deficiency","Anemia"],"enrollment":0,"completionDate":"2018-12"},{"nctId":"NCT01217840","phase":"NA","title":"Effect of Vitamin D Supplementation on Inflammation and Cardiometabolic Risk Factors in Obese Adolescents","status":"COMPLETED","sponsor":"Stanford University","startDate":"2010-09","conditions":["Obesity"],"enrollment":40,"completionDate":"2012-08"},{"nctId":"NCT01004354","phase":"NA","title":"Vitamin D Supplementation in Psychiatric Illnesses","status":"COMPLETED","sponsor":"University of Massachusetts, Worcester","startDate":"2009-06","conditions":["Obesity","Vitamin D Deficiency","Psychosis","Schizophrenia","Schizoaffective Disorder"],"enrollment":12,"completionDate":"2010-06"},{"nctId":"NCT01835691","phase":"NA","title":"Differential Effects of Ergocalciferol and Cholecalciferol Therapies in Chronic Kidney Disease","status":"COMPLETED","sponsor":"University of Kansas Medical Center","startDate":"2011-10","conditions":["Chronic Kidney Disease"],"enrollment":44,"completionDate":"2015-06"},{"nctId":"NCT03228862","phase":"PHASE4","title":"Optimal Doses of Ergocalciferol Supplementation for Treatment of Hypovitaminosis D in Adults","status":"UNKNOWN","sponsor":"Chulalongkorn University","startDate":"2017-05-01","conditions":["Vitamin D2 Supplementation in Vitamin D Insufficiency"],"enrollment":360,"completionDate":"2018-02-01"},{"nctId":"NCT01320722","phase":"PHASE3","title":"Study of Vitamin D and Uric Acid Lowering on Kidney and Blood Vessel Function","status":"COMPLETED","sponsor":"Brigham and Women's Hospital","startDate":"2011-03","conditions":["Renal Function","Endothelial Function","Blood Pressure","Overweight","Obesity"],"enrollment":242,"completionDate":"2015-06"},{"nctId":"NCT03099759","phase":"NA","title":"Vitamin D Raising and Maintaining Blood Serum 25(OH)D3 Levels","status":"COMPLETED","sponsor":"The Cleveland Clinic","startDate":"2016-06-27","conditions":["Vitamin D Deficiency"],"enrollment":49,"completionDate":"2017-05-31"},{"nctId":"NCT01532349","phase":"PHASE2","title":"Vitamin D as a Modifier of Serum Hepcidin in Children With Chronic Kidney Disease","status":"COMPLETED","sponsor":"Johns Hopkins University","startDate":"2012-05","conditions":["Anemia of Chronic Kidney Disease"],"enrollment":34,"completionDate":"2015-04"},{"nctId":"NCT02435771","phase":"PHASE4","title":"Efficacy Of Ergocalciferol In Adults According To BMI","status":"TERMINATED","sponsor":"Walter Reed National Military Medical Center","startDate":"2011-07","conditions":["Obesity","Vitamin D Deficiency"],"enrollment":44,"completionDate":"2017-04"},{"nctId":"NCT01295034","phase":"NA","title":"Vitamin D Supplements for HIV-positive Patients on cART","status":"COMPLETED","sponsor":"Andrea Branch","startDate":"2011-03","conditions":["HIV-associated Co-morbidities"],"enrollment":62,"completionDate":"2015-06"},{"nctId":"NCT01488734","phase":"NA","title":"Bioavailability and Biological Effects of Vitamin D2 Contained in Mushroom","status":"COMPLETED","sponsor":"Icahn School of Medicine at Mount Sinai","startDate":"2011-11","conditions":["Vitamin D Deficiency","Metabolic Syndrome","Prediabetes"],"enrollment":47,"completionDate":"2013-09"},{"nctId":"NCT01173848","phase":"PHASE3","title":"Vitamin D Supplement Study for Stage Three and Four Chronic Kidney Disease (CKD) Patients","status":"TERMINATED","sponsor":"The Cleveland Clinic","startDate":"2010-07","conditions":["Chronic Kidney Disease Stage 3 and 4"],"enrollment":19,"completionDate":"2011-10-18"},{"nctId":"NCT01778114","phase":"NA","title":"Availability of Vitamin D in Orange Juice","status":"COMPLETED","sponsor":"Boston University","startDate":"2006-12","conditions":["Vitamin D Deficiency"],"enrollment":86,"completionDate":"2007-06"},{"nctId":"NCT01815437","phase":"NA","title":"Evaluating Vitamin D Content in Mushrooms","status":"COMPLETED","sponsor":"Boston University","startDate":"2012-01","conditions":["Vitamin D Deficiency"],"enrollment":80,"completionDate":"2013-06"},{"nctId":"NCT00621257","phase":"NA","title":"Vitamin D Levels in Children With IBD","status":"TERMINATED","sponsor":"Boston Children's Hospital","startDate":"2008-01","conditions":["Inflammatory Bowel Disease","Crohn's Disease","Ulcerative Colitis"],"enrollment":134,"completionDate":"2011-03"},{"nctId":"NCT01426347","phase":"NA","title":"Treatment of Vitamin D Deficiency in Patients With Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Johns Hopkins University","startDate":"2009-01","conditions":["Rheumatoid Arthritis","Vitamin D Deficiency"],"enrollment":139,"completionDate":"2012-01"},{"nctId":"NCT02414529","phase":"NA","title":"Efficacy of Vitamin D Therapy on Glucose Homeostasis in Obese Adolescents","status":"COMPLETED","sponsor":"NYU Langone Health","startDate":"2013-11","conditions":["Vitamin D Deficiency"],"enrollment":20,"completionDate":"2015-10"},{"nctId":"NCT00535158","phase":"","title":"Vitamin D 2 to Dialysis Patients","status":"TERMINATED","sponsor":"Brigham and Women's Hospital","startDate":"2008-06-01","conditions":["Kidney Disease","Muscle Weakness","Pain","Fractures, Bone"],"enrollment":18,"completionDate":"2009-06-01"},{"nctId":"NCT02720575","phase":"NA","title":"Evaluation of the Bioavailability of Vitamin D2 in Yeast and Bread","status":"COMPLETED","sponsor":"Boston University","startDate":"2016-01","conditions":["Healthy"],"enrollment":10,"completionDate":"2016-12"},{"nctId":"NCT02132442","phase":"PHASE3","title":"Hepatic Dysfunction, Vitamin D Status, and Glycemic Control in Diabetes","status":"COMPLETED","sponsor":"University of Massachusetts, Worcester","startDate":"2014-03","conditions":["Type 2 Diabetes","Nonalcoholic Fatty Liver Disease","Vitamin D Deficiency"],"enrollment":12,"completionDate":"2016-10"},{"nctId":"NCT00948740","phase":"PHASE2,PHASE3","title":"The Effect of Vitamin D on Urinary Calcium Excretion in Kidney Stone Formers With High Urinary Calcium","status":"WITHDRAWN","sponsor":"Brigham and Women's Hospital","startDate":"2009-08","conditions":["Vitamin D Deficiency","Nephrolithiasis"],"enrollment":0,"completionDate":"2010-06"},{"nctId":"NCT02860663","phase":"NA","title":"Effect of Different Vitamin D Vitamers on Vitamin D Status","status":"COMPLETED","sponsor":"University of Copenhagen","startDate":"2007-08","conditions":["Vitamin D Status"],"enrollment":14,"completionDate":"2008-04"},{"nctId":"NCT01170494","phase":"NA","title":"Effect of Vitamin D Oral Supplements on 25 OH Vitamin D Levels","status":"COMPLETED","sponsor":"King Faisal Specialist Hospital & Research Center","startDate":"2013-02","conditions":["Vitamin D Deficiency"],"enrollment":279,"completionDate":"2016-04"},{"nctId":"NCT01774812","phase":"PHASE2","title":"Vitamin D and Cardiac Autonomic Tone in Hemodialysis","status":"COMPLETED","sponsor":"University of Calgary","startDate":"2013-01","conditions":["Cardiovascular Disease","Sudden Cardiac Death"],"enrollment":56,"completionDate":"2015-03"},{"nctId":"NCT02011828","phase":"PHASE1","title":"Ergocalciferol Therapy in Calcidiol Deficient, Hemodialysis Patients on Therapeutic Doses of Paricalcitol","status":"COMPLETED","sponsor":"University of Utah","startDate":"2009-05","conditions":["Inflammation","Insulin Resistance"],"enrollment":58,"completionDate":"2011-01"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{"route":"Oral","formulation":"Capsule, Emulsion","formulations":[{"form":"CAPSULE","route":"ORAL","productName":"ERGOCALCIFEROL"},{"form":"CAPSULE","route":"ORAL","productName":"Ergocalciferol"},{"form":"CAPSULE","route":"ORAL","productName":"Ergocalciferol (Vitamin D2)"},{"form":"CAPSULE","route":"ORAL","productName":"Ergocalciferol Capsules,"},{"form":"CAPSULE","route":"ORAL","productName":"VITAMIN D"},{"form":"CAPSULE","route":"ORAL","productName":"Vitamin D"},{"form":"CAPSULE, LIQUID FILLED","route":"ORAL","productName":"Ergocalciferol"},{"form":"CAPSULE, LIQUID FILLED","route":"ORAL","productName":"Vitamin D"},{"form":"CAPSULE, LIQUID FILLED","route":"ORAL","productName":"DRISDOL"},{"form":"EMULSION","route":"INTRAVENOUS","productName":"Vitalipid N"}]},"_patentsChecked":true,"crossReferences":{"NUI":"N0000146009","MMSL":"1067","NDDF":"001013","UNII":"VS041H42XC","VUID":"4017629","CHEBI":"CHEBI:28934","VANDF":"4017629","INN_ID":"382","RXNORM":"11253","UMLSCUI":"C0014695","chemblId":"CHEMBL1536","ChEMBL_ID":"CHEMBL1536","KEGG_DRUG":"D00187","DRUGBANK_ID":"DB00153","PDB_CHEM_ID":" D2V","PUBCHEM_CID":"5280793","SNOMEDCT_US":"11563006","MESH_DESCRIPTOR_UI":"D004872"},"formularyStatus":[],"_enricherVersion":"v2","_offLabelChecked":true,"developmentCodes":[],"ownershipHistory":[{"period":"1941-","companyName":"Sanofi","relationship":"Original Developer"},{"period":"present","companyName":"Esjay Pharma","relationship":"Current Owner"}],"publicationCount":933,"therapeuticAreas":["Metabolic"],"atcClassification":{"source":"DrugCentral","atcCode":"A11CC01","allCodes":["A11CC01"]},"biosimilarFilings":[],"originalDeveloper":"Sanofi Aventis Us","recentPublications":[{"date":"2026 Mar","pmid":"41777703","title":"Vitamin D deficiency and disease conditions relevant to: Orthopaedic translation.","journal":"Journal of orthopaedic translation"},{"date":"2026","pmid":"41219601","title":"Vitamin D and Fracture Healing.","journal":"Advances in experimental medicine and biology"},{"date":"2026","pmid":"41219598","title":"Vitamin D and Brain Health.","journal":"Advances in experimental medicine and biology"},{"date":"2025","pmid":"41163646","title":"A 3-Year-Old Child With Incidental High-Dose Vitamin D Intoxication: A Case Report and Literature Review.","journal":"Case reports in endocrinology"},{"date":"2025 Oct 15","pmid":"41154052","title":"Himalayan Mushrooms as a Natural Source of Ergosterol and Vitamin D(2): A Review of Nutraceutical and Functional Food Perspectives.","journal":"Foods (Basel, Switzerland)"}],"companionDiagnostics":[],"genericManufacturers":13,"_genericFilersChecked":true,"genericManufacturerList":["Bionpharma","Chartwell Molecular","Chartwell Rx","Chase Chem","Everylife","Impax Labs","Lilly","Onesource Specialty","Puracap Pharm Llc","Sigmapharm Labs Llc","Sun Pharm Inds Inc","Vitarine","West Ward"],"status":"approved","companyName":"Esjay Pharma","companyId":"esjay-pharma","modality":"Small molecule","firstApprovalDate":"1941","enrichmentLevel":3,"visitCount":0,"regulatoryByCountry":[{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"1941-01-11T00:00:00.000Z","mah":"SANOFI AVENTIS US","brand_name_local":null,"application_number":""},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":"1941-01-11T00:00:00.000Z","mah":"SANOFI AVENTIS US","brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":"1941-01-11T00:00:00.000Z","mah":"SANOFI AVENTIS US","brand_name_local":null,"application_number":null},{"country_code":"SA","regulator":"SFDA","status":"likely_approved","approval_date":"1941-01-11T00:00:00.000Z","mah":"SANOFI AVENTIS US","brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":"1941-01-11T00:00:00.000Z","mah":"SANOFI AVENTIS US","brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":"1941-01-11T00:00:00.000Z","mah":"SANOFI AVENTIS US","brand_name_local":null,"application_number":null},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"1975-06-19T00:00:00.000Z","mah":"ESJAY PHARMA","brand_name_local":null,"application_number":"NDA003444"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"1996-08-28T00:00:00.000Z","mah":"BIONPHARMA","brand_name_local":null,"application_number":"ANDA080704"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2009-05-20T00:00:00.000Z","mah":"CHARTWELL RX","brand_name_local":null,"application_number":"ANDA040833"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2010-08-03T00:00:00.000Z","mah":"ONESOURCE SPECIALTY","brand_name_local":null,"application_number":"ANDA090455"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2018-12-07T00:00:00.000Z","mah":"PURACAP PHARM LLC","brand_name_local":null,"application_number":"ANDA204276"},{"country_code":"ZA","regulator":"SAHPRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"TW","regulator":"TFDA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"HK","regulator":"DH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"BR","regulator":"ANVISA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"MX","regulator":"COFEPRIS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AR","regulator":"ANMAT","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"TR","regulator":"TITCK","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IN","regulator":"CDSCO","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"TH","regulator":"FDA-TH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"MY","regulator":"NPRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"PH","regulator":"FDA-PH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"CO","regulator":"INVIMA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":4,"withResults":0},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T00:41:33.495317+00:00","fieldsConflicting":1,"overallConfidence":0.8},"verificationStatus":"verified","dataCompleteness":{"mechanism":false,"indications":true,"safety":true,"trials":true,"score":3}}